Pharmacogenetics and pharmacogenomics in rheumatology

Zoltán Szekanecz, Bertalan Meskó, Szilard Poliska, Andrea Váncsa, Szilvia Szamosi, Edit Végh, Enikö Simkovics, Judit Laki, Júlia Kurkó, Timea Besenyei, Katalin Mikecz, Tibor T. Glant, Laszlo Nagy

Research output: Contribution to journalArticle

Abstract

Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

Original languageEnglish (US)
Pages (from-to)325-333
Number of pages9
JournalImmunologic Research
Volume56
Issue number2-3
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Pharmacogenetics
Rheumatology
Biological Products
Genes
Antirheumatic Agents
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Anti-Inflammatory Agents
Cytokines
Precision Medicine
Genetic Polymorphisms
Chemokines
Adrenal Cortex Hormones
Safety

Keywords

  • Biologics
  • DMARDs
  • Genetic signature
  • NSAIDs
  • Pharmacogenetics
  • Pharmacogenomics
  • Rheumatoid arthritis
  • SNP

ASJC Scopus subject areas

  • Immunology

Cite this

Szekanecz, Z., Meskó, B., Poliska, S., Váncsa, A., Szamosi, S., Végh, E., ... Nagy, L. (2013). Pharmacogenetics and pharmacogenomics in rheumatology. Immunologic Research, 56(2-3), 325-333. https://doi.org/10.1007/s12026-013-8405-z

Pharmacogenetics and pharmacogenomics in rheumatology. / Szekanecz, Zoltán; Meskó, Bertalan; Poliska, Szilard; Váncsa, Andrea; Szamosi, Szilvia; Végh, Edit; Simkovics, Enikö; Laki, Judit; Kurkó, Júlia; Besenyei, Timea; Mikecz, Katalin; Glant, Tibor T.; Nagy, Laszlo.

In: Immunologic Research, Vol. 56, No. 2-3, 01.07.2013, p. 325-333.

Research output: Contribution to journalArticle

Szekanecz, Z, Meskó, B, Poliska, S, Váncsa, A, Szamosi, S, Végh, E, Simkovics, E, Laki, J, Kurkó, J, Besenyei, T, Mikecz, K, Glant, TT & Nagy, L 2013, 'Pharmacogenetics and pharmacogenomics in rheumatology', Immunologic Research, vol. 56, no. 2-3, pp. 325-333. https://doi.org/10.1007/s12026-013-8405-z
Szekanecz Z, Meskó B, Poliska S, Váncsa A, Szamosi S, Végh E et al. Pharmacogenetics and pharmacogenomics in rheumatology. Immunologic Research. 2013 Jul 1;56(2-3):325-333. https://doi.org/10.1007/s12026-013-8405-z
Szekanecz, Zoltán ; Meskó, Bertalan ; Poliska, Szilard ; Váncsa, Andrea ; Szamosi, Szilvia ; Végh, Edit ; Simkovics, Enikö ; Laki, Judit ; Kurkó, Júlia ; Besenyei, Timea ; Mikecz, Katalin ; Glant, Tibor T. ; Nagy, Laszlo. / Pharmacogenetics and pharmacogenomics in rheumatology. In: Immunologic Research. 2013 ; Vol. 56, No. 2-3. pp. 325-333.
@article{c8a438e838ee4ee8b7ff685302bf67ec,
title = "Pharmacogenetics and pharmacogenomics in rheumatology",
abstract = "Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.",
keywords = "Biologics, DMARDs, Genetic signature, NSAIDs, Pharmacogenetics, Pharmacogenomics, Rheumatoid arthritis, SNP",
author = "Zolt{\'a}n Szekanecz and Bertalan Mesk{\'o} and Szilard Poliska and Andrea V{\'a}ncsa and Szilvia Szamosi and Edit V{\'e}gh and Enik{\"o} Simkovics and Judit Laki and J{\'u}lia Kurk{\'o} and Timea Besenyei and Katalin Mikecz and Glant, {Tibor T.} and Laszlo Nagy",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/s12026-013-8405-z",
language = "English (US)",
volume = "56",
pages = "325--333",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Pharmacogenetics and pharmacogenomics in rheumatology

AU - Szekanecz, Zoltán

AU - Meskó, Bertalan

AU - Poliska, Szilard

AU - Váncsa, Andrea

AU - Szamosi, Szilvia

AU - Végh, Edit

AU - Simkovics, Enikö

AU - Laki, Judit

AU - Kurkó, Júlia

AU - Besenyei, Timea

AU - Mikecz, Katalin

AU - Glant, Tibor T.

AU - Nagy, Laszlo

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

AB - Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

KW - Biologics

KW - DMARDs

KW - Genetic signature

KW - NSAIDs

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Rheumatoid arthritis

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=84879551758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879551758&partnerID=8YFLogxK

U2 - 10.1007/s12026-013-8405-z

DO - 10.1007/s12026-013-8405-z

M3 - Article

VL - 56

SP - 325

EP - 333

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 2-3

ER -